Serial monitoring of circulating cell-free tumor DNA as measured by duplex sequencing in older patients with acute myeloid leukemia who receive azacitidine+venetoclax +/- immune checkpoint blockade

通过双重测序对接受阿扎胞苷维奈托克/免疫检查点阻断的老年急性髓系白血病患者的循环游离肿瘤 DNA 进行连续监测

基本信息

  • 批准号:
    10337831
  • 负责人:
  • 金额:
    $ 10.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-01 至 2022-02-28
  • 项目状态:
    已结题

项目摘要

ABSTRACT IDH1 and IDH2 mutations are present in 15 to 20% of newly diagnosed cases of AML. They are associated with the production of the onco-metabolite 2-Hydroxyglutarate and a distinctive clonal landscape. IDH targeted inhibitors have been developed with success over the last decade but primary or secondary resistances remain extremely common. Resistance is driven by a variety of mechanisms including isotype switch, IDH secondary point mutation, acquisition of RTK mutation (such as RAS), or the development of IDH negative clones. Identifying the mechanisms driving resistance in a patient is crucial to be able to develop strategies to prevent and treat progressions. Our group has demonstrated that the presence IDH mutation induces a “BRCAness phenotype” in cells and a sensitivity to PARP inhibitors. These in vitro and in vivo findings were translated in a phase 2 study of Olaparib in IDH mutated AML and MDS (the PRIME study, CTEP #10264). For patients treated with Olaparib, we expect to see a similar pattern of resistance mechanisms as the one seen with IDH inhibitors and in order to optimize our therapies, we need to have a clear picture of the clonal complexity at the different points of the treatment. Conventional “Bulk sequencing” can provide some information but the level of granularity of the data may not be sufficient in all cases. Single cell sequencing may overcome these limitations and the new generation of platforms, such as the Tapestri platform, allow integrated and reliable workflows that can process a large volume of samples. More recently, multi-omics approaches have been developed with concomitant immunophenotyping and this allows to refine even more the results by allowing to focus on different cellular subsets. In this proposal, we use Single Cell DNA Sequencing and multi-omics approach to evaluate the clonal architecture before and during treatment with olaparib. Besides giving us more insights on the mode of action of olaparib, this approach will help us define the mechanisms of primary and secondary resistance to olaparib in this population. Consequently, this will guide our future strategies to overcome these resistances. Second, we will correlate SCS data with clinical response and evaluate if SCS has the potential to be used as a biomarker of response in a multicenter trial setting. 2
抽象的 15% 至 20% 的新诊断 AML 病例中存在 IDH1 和 IDH2 突变。他们是 与肿瘤代谢物 2-羟基戊二酸的产生和独特的克隆景观有关。异丁烯酸脱氢酶 过去十年来,靶向抑制剂已取得成功,但主要或次要耐药性 仍然非常普遍。耐药性由多种机制驱动,包括同型转换、IDH 继发点突变、获得 RTK 突变(例如 RAS)或 IDH 阴性 克隆。确定患者耐药性的机制对于制定策略至关重要 预防和治疗进展。我们的小组已经证明 IDH 突变的存在会诱导 细胞中的“BRCAness 表型”和对 PARP 抑制剂的敏感性。这些体外和体内研究结果 转化为奥拉帕尼治疗 IDH 突变 AML 和 MDS 的 2 期研究(PRIME 研究,CTEP #10264)。为了 对于接受奥拉帕尼治疗的患者,我们预计会看到与接受奥拉帕尼治疗的患者相似的耐药机制模式 IDH 抑制剂,为了优化我们的疗法,我们需要清楚地了解克隆的复杂性 治疗的不同点。传统的“批量测序”可以提供一些信息,但水平 数据的粒度可能不足以满足所有情况。单细胞测序可以克服这些限制 Tapestri 平台等新一代平台可实现集成且可靠的工作流程, 可处理大量样品。最近,多组学方法已被开发出来 伴随免疫表型分析,这可以通过关注不同的结果来进一步完善结果 细胞亚群。 在本提案中,我们使用单细胞 DNA 测序和多组学方法来评估克隆 奥拉帕尼治疗前和治疗期间的结构。除了让我们对作用方式有更多的了解 奥拉帕尼,这种方法将帮助我们定义奥拉帕尼的主要和次要耐药机制 人口。因此,这将指导我们未来克服这些阻力的策略。其次,我们将 将 SCS 数据与临床反应相关联,并评估 SCS 是否有潜力用作以下疾病的生物标志物 多中心试验环境中的反应。 2

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PATRICIA M. LORUSSO其他文献

PATRICIA M. LORUSSO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PATRICIA M. LORUSSO', 18)}}的其他基金

Supplement to UM1 grant for NCI's Early Therapeutics Clinical Trials Network (ETCTN)
NCI 早期治疗临床试验网络 (ETCTN) 的 UM1 补助金补充
  • 批准号:
    10678278
  • 财政年份:
    2022
  • 资助金额:
    $ 10.83万
  • 项目类别:
VICKtOrY Early Clinical Trials Consortium
VICKtory 早期临床试验联盟
  • 批准号:
    10644207
  • 财政年份:
    2022
  • 资助金额:
    $ 10.83万
  • 项目类别:
Integration of single cell sequencing as a biomarker of PARP inhibitor response for IDH1 and IDH2 mutated AML and MDS
整合单细胞测序作为 IDH1 和 IDH2 突变 AML 和 MDS 的 PARP 抑制剂反应的生物标志物
  • 批准号:
    10337798
  • 财政年份:
    2021
  • 资助金额:
    $ 10.83万
  • 项目类别:
Administrative Supplement for VICKtOrY Early Clinical Trials Consortium
VICKtory 早期临床试验联盟的行政补充
  • 批准号:
    10392078
  • 财政年份:
    2021
  • 资助金额:
    $ 10.83万
  • 项目类别:
ViKTriY Early Clinical Trials Consortium (ECTC)
ViKTriY 早期临床试验联盟 (ECTC)
  • 批准号:
    8725330
  • 财政年份:
    2014
  • 资助金额:
    $ 10.83万
  • 项目类别:
ViKTriY Early Clinical Trials Consortium (ECTC)
ViKTriY 早期临床试验联盟 (ECTC)
  • 批准号:
    8890125
  • 财政年份:
    2014
  • 资助金额:
    $ 10.83万
  • 项目类别:
VICKtOrY Early Clinical Trials Consortium
VICKtory 早期临床试验联盟
  • 批准号:
    10784848
  • 财政年份:
    2014
  • 资助金额:
    $ 10.83万
  • 项目类别:
Early Clinical Trials of New Anti-Cancer Agents
新型抗癌药物的早期临床试验
  • 批准号:
    7886178
  • 财政年份:
    2009
  • 资助金额:
    $ 10.83万
  • 项目类别:
Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU
NCI研究的相关研究
  • 批准号:
    7761433
  • 财政年份:
    2009
  • 资助金额:
    $ 10.83万
  • 项目类别:
Correlative Studies for NCI Study #7977: Phase I trial of ABT-888 Plus Irinotecan
NCI研究的相关研究
  • 批准号:
    7525941
  • 财政年份:
    2008
  • 资助金额:
    $ 10.83万
  • 项目类别:

相似海外基金

Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
  • 批准号:
    19K08356
  • 财政年份:
    2019
  • 资助金额:
    $ 10.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
  • 批准号:
    23501309
  • 财政年份:
    2011
  • 资助金额:
    $ 10.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556971
  • 财政年份:
    1980
  • 资助金额:
    $ 10.83万
  • 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556968
  • 财政年份:
    1980
  • 资助金额:
    $ 10.83万
  • 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
  • 批准号:
    3889304
  • 财政年份:
  • 资助金额:
    $ 10.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了